BS-181 is primarily used in research and development within the field of oncology. It functions as a selective inhibitor of CDK7 (Cyclin-Dependent Kinase 7), making it a valuable tool for studying the role of CDK7 in cancer cell proliferation and transcription regulation. Researchers utilize BS-181 to investigate its potential in disrupting the cell cycle of cancer cells, particularly in breast cancer and other malignancies. Its application extends to preclinical studies aimed at understanding the mechanisms of CDK7 inhibition and its effects on tumor growth. Additionally, BS-181 is employed in drug discovery efforts to develop targeted therapies for cancers that are driven by dysregulated CDK7 activity.